Today: 17 May 2026
Oklo Stock Pops After NRC Fast-Track Approval. The Nuclear Startup Still Has a Lot to Prove
7 May 2026
2 mins read

Oklo Stock Pops After NRC Fast-Track Approval. The Nuclear Startup Still Has a Lot to Prove

NEW YORK, May 7, 2026, 09:26 EDT

Oklo Inc. shares looked poised to pull back at Thursday’s open, cooling off after a rapid surge. Investors are sizing up the company’s swift U.S. regulatory clearance for its Aurora powerhouse project in Idaho, but the path to commercial operation remains anything but short.

Oklo said Wednesday that the U.S. Nuclear Regulatory Commission has signed off on its Principal Design Criteria topical report, clearing an early regulatory hurdle for the Aurora project. The report, which outlines baseline safety, reliability, and performance standards, acts as a foundational document that can be referenced in future filings instead of being reassessed each time. According to Oklo, the review wrapped up in less than half the usual period. CEO Jacob DeWitte pointed to what he called “timely engagement by the regulator.” Oklo

Licensing speed is suddenly front and center for advanced nuclear firms eager to convert investor appetite into actual plants. Oklo, for its part, isn’t peddling reactor designs; its bet is on building, owning, and running the powerhouses itself, then selling the electricity. The company’s regulatory game plan hinges on a repeatable licensing process, aimed at tightening future review scopes.

The move drops into a market already chasing power stories linked to artificial intelligence and data centers. Major tech buyers are sharpening the revenue picture for the sector, yet who shoulders construction and delay risk still dictates financing. “They create the revenue certainty that commercial banks will require for the construction debt,” BMI senior analyst Shioly Dong told Reuters last month, talking about these power deals. Tim Winter, who manages the Gabelli Utilities Fund, cut to the chase: “The industry needs someone to take on the risks.” Reuters

Oklo ended Wednesday at $79.62. Ahead of the U.S. market open Thursday, Google Finance put shares at $77.30, off 2.91%.

NuScale Power and Nano Nuclear Energy shares climbed in early action, joining Oklo in the broader advanced-nuclear rally. The moves kept the trade from being just about one stock.

Oklo’s appeal, in part, comes from surging demand among big electricity buyers. Earlier in 2024, the company landed a non-binding deal to supply power to data center operator Switch, eyeing Aurora reactor deployments that could total as much as 12 gigawatts by 2044. Each Aurora unit was rated for 15 megawatts electric at that time, according to Reuters.

Fuel rounds out the picture here. Back in October, Oklo announced that Europe’s newcleo aimed to invest as much as $2 billion toward advanced fuel fabrication and manufacturing in the U.S. Sweden’s Blykalla was looking at a potential co-investment. At the time, DeWitte said tapping surplus plutonium could “accelerate the deployment of multiple gigawatts,” offering a bridge while uranium enrichment and recycling catch up. Reuters

Still, approval doesn’t put Oklo across the commercial finish line. According to its most recent annual filing, the company hasn’t built a single powerhouse or locked in a binding power purchase agreement—no deals in place to run a plant or actually supply electricity or heat. Oklo warned it anticipates heavy spending and ongoing losses until, and unless, its powerhouses turn commercially viable—which, it noted, might never occur.

Oklo sits on $1.41 billion in cash, cash equivalents and marketable debt securities as of the end of 2025, but the buildout won’t be cheap. The company ended the year with a $105.7 million net loss, burning through $82.2 million in operating cash.

Oklo is set to deliver its first-quarter 2026 results after the bell on May 12. CEO Jacob DeWitte and CFO Craig Bealmear will handle the call, according to the company’s announcement. Investors can find more details in the release.

Oklo gets a clearer regulatory marker with the NRC decision, for now. The real hurdles—fuel, construction, financing, and locking in customers—are still out there. That’s likely where the next test for the stock comes in.

Stock Market Today

  • Carnival (CCL) Removed from FTSE Indices Amid Share Price Weakness, Valuation Seen 34.6% Undervalued
    May 16, 2026, 7:46 PM EDT. Carnival Corp (CCL) has been dropped from major FTSE indices including FTSE 100 and 250, prompting potential forced selling by index funds. Its share price is down across recent timeframes despite positive 1- and 3-year shareholder returns. Market sentiment is mixed, but Simply Wall St analysis values Carnival at $37.70, about 34.6% above the current $24.64 price, citing growth from exclusive private destinations and expanding leisure demand. Risks include geopolitical instability, high fuel costs, and substantial debt, which could pressure margins and cash flows. Investors are advised to assess key opportunities and risks carefully amid this valuation gap and market volatility.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Why Fluence Energy Stock Is Surging: Data-Center Deals Put $5.6 Billion Backlog in Focus
Previous Story

Why Fluence Energy Stock Is Surging: Data-Center Deals Put $5.6 Billion Backlog in Focus

Snowflake Stock Just Jumped. Now Comes the AI Test Wall Street Won’t Ignore
Next Story

Snowflake Stock Just Jumped. Now Comes the AI Test Wall Street Won’t Ignore

Go toTop